MetaCap

Cullinan Therapeutics (CGEM) vs Iambic Therapeutics (IAM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Iambic Therapeutics is the larger company by market cap ($621.4 million vs $577.1 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CGEM-36.50%IAM-30.67%
+30%-10%-50%
Oct 15, 20261 yearNov 20, 2026
CGEM-31.25%IAM-44.94%
+20%-21%-61%
Oct 12, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CGEM versus IAM key metrics
MetricCGEMIAM
Share price$8.89$13.11
Market cap$577.15M$621.42M
1-day change-1.98%-8.06%
YTD return-14.11%—
1-year return-6.12%—
5-year return-51.21%—
EPS (TTM)$-3.09$-2.69
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-219.88M—
52-week high$23.19$25.00
52-week low$8.47$9.60
Distance from 52-week high-61.66%-47.56%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+285.49%+107.86%
Average volume997.14K714.92K
Shares outstanding64.92M47.40M
Employees109171
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Cullinan Therapeutics

CGEM stock →

Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 109 employees

About Iambic Therapeutics

IAM stock →

Iambic Therapeutics, Inc. operates as a biotechnology company that develops therapeutics from its AI discovery platform that optimizes target product profiles and drug candidates in the United States and Internationally.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 171 employees

CGEM vs IAM FAQ

Which is bigger, Cullinan Therapeutics or Iambic Therapeutics?

Iambic Therapeutics (IAM) is larger, with a market capitalization of $621.42M compared with $577.15M for Cullinan Therapeutics (CGEM).

Are Cullinan Therapeutics and Iambic Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons